1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.43 (0.99) to $43.73 on average volume Thus far, 4.2 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.9 million shares. The stock has ranged in price between $43.35-$44.14 after having opened the day at $43.36 as compared to the previous trading day's close of $43.30.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $70.3 billion and is part of the health care sector. The company has a P/E ratio of 48.1, above the S&P 500 P/E ratio of 17.7. Shares are up 32.9% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead